- The recommended dose is 30 mcg injected intramuscularly once a week.
- Treatment may be started at 7.5 mcg weekly and increased by 7.5 mcg weekly until the full dose of 30 mcg is reached.
DRUG CLASS AND MECHANISM:
- Interferon beta-1a (Avonex) is a protein produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary Cells into which the human interferon beta genes have been introduced. It is used for treating multiple sclerosis (MS). Interferon beta-1a is designed to be identical to interferon beta that is naturally produced by various cells in the body. Interferon beta has antiviral properties and plays a role in regulating the immune response. The exact mechanism by which interferon beta-1a works in the body to treat MS is not known. Interferon beta-1a does not cure MS. Rather, it helps to decrease the number of flare-ups and slows the occurrence of some of the physical disability that commonly occurs in the disease.
- Avonex was approved by the FDA in 1996.
REFERENCE: FDA Prescribing Information
Quick GuideMultiple Sclerosis Pictures Slideshow: Causes, Symptoms and Treatment
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.